Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Oct 18;3(10):100786.
doi: 10.1016/j.xcrm.2022.100786.

Accelerated development of malaria monoclonal antibodies

Narimane Nekkab  1 , Melissa A Penny  2
Affiliations
Comment

Accelerated development of malaria monoclonal antibodies

Narimane Nekkab et al. Cell Rep Med. .

Abstract

L9LS, a potent and safe antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection in a phase 1 trial in healthy adults.1 These promising results are the first of many to usher in a potential new era of malaria prevention.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests. N.N. and M.P. are funded by the Bill and Melinda Gates Foundation (INV-002562 to MAP) to model Target Product Profiles of next-generation seasonal interventions.

Comment on

  • Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.
    Wu RL, Idris AH, Berkowitz NM, Happe M, Gaudinski MR, Buettner C, Strom L, Awan SF, Holman LA, Mendoza F, Gordon IJ, Hu Z, Campos Chagas A, Wang LT, Da Silva Pereira L, Francica JR, Kisalu NK, Flynn BJ, Shi W, Kong WP, O'Connell S, Plummer SH, Beck A, McDermott A, Narpala SR, Serebryannyy L, Castro M, Silva R, Imam M, Pittman I, Hickman SP, McDougal AJ, Lukoskie AE, Murphy JR, Gall JG, Carlton K, Morgan P, Seo E, Stein JA, Vazquez S, Telscher S, Capparelli EV, Coates EE, Mascola JR, Ledgerwood JE, Dropulic LK, Seder RA; VRC 614 Study Team. Wu RL, et al. N Engl J Med. 2022 Aug 4;387(5):397-407. doi: 10.1056/NEJMoa2203067. N Engl J Med. 2022. PMID: 35921449 Free PMC article. Clinical Trial.

References

    1. Wu R.L., Idris A.H., Berkowitz N.M., Happe M., Gaudinski M.R., Buettner C., Strom L., Awan S.F., Holman L.A., Mendoza F., et al. Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria. N. Engl. J. Med. 2022;387:397–407. doi: 10.1056/NEJMoa2203067. - DOI - PMC - PubMed
    1. Anti-malaria MAb in Mali. Updated September 21, 2022. Accessed September 21, 2022. https://ClinicalTrials.gov/show/NCT04329104.
    1. Kisalu N.K., Idris A.H., Weidle C., Flores-Garcia Y., Flynn B.J., Sack B.K., Murphy S., Schön A., Freire E., Francica J.R., et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat. Med. 2018;24:408–416. doi: 10.1038/nm.4512. - DOI - PMC - PubMed
    1. Wang L.T., Pereira L.S., Flores-Garcia Y., O’Connor J., Flynn B.J., Schön A., Hurlburt N.K., Dillon M., Yang A.S.P., Fabra-García A., et al. A potent anti-Malarial human monoclonal antibody targets circumsporozoite protein minor repeats and Neutralizes sporozoites in the liver. Immunity. 2020;53:733–744.e8. doi: 10.1016/j.immuni.2020.08.014. - DOI - PMC - PubMed
    1. Kisalu N.K., Pereira L.D., Ernste K., Flores-Garcia Y., Idris A.H., Asokan M., Dillon M., MacDonald S., Shi W., Chen X., et al. Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention. JCI Insight. 2021;6 doi: 10.1172/jci.insight.143958. - DOI - PMC - PubMed

Publication types

LinkOut - more resources